JBC Oz Biosciences

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robinson, MeganJ.
Right arrow Articles by Cobb, MelanieH.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robinson, MeganJ.
Right arrow Articles by Cobb, MelanieH.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 271, Number 47, Issue of November 22, 1996 pp. 29734-29739
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Contributions of the Mitogen-activated Protein (MAP) Kinase Backbone and Phosphorylation Loop to MEK Specificity*

(Received for publication, July 19, 1996, and in revised form, September 6, 1996)

Megan J. Robinson Dagger , Mangeng Cheng Dagger §, Andrei Khokhlatchev Dagger §, Doug Ebert Dagger §, Natalie Ahn , Kun-Liang Guan par , Bernd Stein **, Elizabeth Goldsmith Dagger Dagger and Melanie H. Cobb Dagger §§

From the Departments of Dagger  Pharmacology and Dagger Dagger  Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75235, the  Howard Hughes Medical Institute, University of Colorado, Boulder, Colorado 80309, the par  Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109, and ** Signal Pharmaceuticals Inc., San Diego, California 92121

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

To examine the specificity of MEKs for MAP kinase family members, we determined the abilities of several MEK isoforms to phosphorylate mutants of the MAP kinase ERK2 and the related kinase ERK3 which are modified in the phosphorylation loop. The ERK2 mutants included mutations of the two phosphorylation sites, mutations of the acidic residue between these two sites, and mutations that shorten the length of this loop. All mutants were tested for phosphorylation by six mammalian MEKs and compared with several wild type MAP kinases. MEK1 and MEK2 phosphorylate a majority of the ERK2 mutants. MEK2 but not MEK1 will phosphorylate ERK3. Alteration of the residue between the two phosphorylation sites neither dramatically affected the activity of MEK1 and MEK2 toward ERK2 nor conferred recognition by other MEKs. Likewise, reduction of the length of the phosphorylation loop only partially reduces recognition by MEK1 and MEK2 but does not promote recognition by other MEKs. Thus other yet to be identified factors must contribute to the specificity of MEK recognition of MAP kinases.


INTRODUCTION

Intracellular signaling pathways are triggered in response to extracellular stimuli, including growth factors, heat shock, inflammatory cytokines, and ultraviolet light (1, 2). These pathways allow the cell to respond in an appropriate fashion, through proliferation, expression of differentiated properties, or protective responses to environmental insult (1, 2). Mitogen-activated protein (MAP)1 kinase cascades contribute to these responses and are highly conserved in both yeast and mammalian systems (3, 4). MAP kinase cascades consist of three protein kinases acting in series: a MAP kinase, a MAP kinase kinase or MAP/ERK kinase (MEK), and a MAP/ERK kinase kinase or MEKK. In mammalian cells at least three such cascades have been well described (Fig. 1A): the MEK1/2-ERK1/2 module, the MEK3/4/6-p38 module, and the MEK4-stress-activated protein kinase/c-Jun-N-terminal protein kinase (SAPK/JNK) module (1, 2). In addition, two less studied pathways containing ERK3 kinase-ERK3 and MEK5-ERK5 have been identified (5, 6, 7).


Fig. 1. MAP kinase modules and phosphorylation lips. Panel A, three MAP kinase cascades. Panel B, phosphorylation lips. The residues deleted in ERK2Delta 4 and ERK2Delta 6 are underlined. The residue that lies between the two sites of MEK phosphorylation is shown in shadow text.
[View Larger Version of this Image (29K GIF file)]


Within these modules MEKs appear to be singularly specific activators of MAP kinases (8, 9, 10). MEKs are a family of dual specificity kinases that phosphorylate MAP kinases on both a threonine and a tyrosine residue (11). MEKs have an unusually restricted substrate specificity in that they have no other known substrates beyond MAP kinases (12). Furthermore, each MEK isoform selectively phosphorylates only a subset of the MAP kinase family members. Finally, MEKs do not recognize denatured protein or peptides derived from the MAP kinases (12); apparently the three-dimensional structure of the MAP kinase is important for MEK recognition.

The sequence identity among ERK1/2, JNKs, and p38 MAP kinases is ~40-45%. These three mammalian MAP kinases have a common regulatory mechanism requiring phosphorylation by MEKs of a threonine and a tyrosine in comparable positions in the loop known as the phosphorylation lip. We examined differences among family members in that loop which might contribute to the specificity of recognition by upstream MEKs. First, the three kinases ERK2, p38, and SAPKbeta have a different intervening residue (Glu, Gly, and Pro, respectively) between the two sites of phosphorylation (1). In addition, the yeast MAP kinase SMK1 and other related kinases such as the KKIALRE kinase (1, 13) contain different residues (Asn and Asp, respectively) at this position (Fig. 1B). It has been suggested that this residue determines the ability of a given MEK to phosphorylate a particular MAP kinase (14, 15). Second, the three MAP kinases differ in the length of their phosphorylation lips. ERK2 has the longest lip, at 25 amino acids, following the conserved DFG extending to the conserved APE residues. SAPK has a lip length of 21 amino acids, and p38 has the shortest lip length at 19 residues.

To probe features of the MAP kinase phosphorylation lip which are important for MEK recognition and activation, we constructed the following ERK2 mutants: 1) mutations of the sites of MEK phosphorylation; 2) mutations of the residue between the two sites of MEK phosphorylation; and 3) mutations to shorten the length of the phosphorylation lip. We then tested the ability of all six available MEKs as well as constitutively active mutants of MEK1 and MEK2 to phosphorylate and activate ERK2, ERK3, p38, SAPKbeta , and ERK2 mutants. Of the MEKs tested, only MEK1 and MEK2 phosphorylated ERK2. None of the lip changes destroyed the recognition of ERK2 by MEK1 and MEK2 or caused ERK2 to be recognized by any other MEK isoforms. Interestingly, however, the mutants allowed us to identify specificity differences between MEK1 and MEK2. Thus, although the phosphorylation lip is important for interaction of a MEK isoform with its downstream MAP kinase, other factors must direct the specificity of this interaction.


EXPERIMENTAL PROCEDURES

Proteins

The His6-p38 construct was the generous gift of Jiahuia Han and was purified over nickel NTA-agarose (Qiagen) as described previously (11) as were all histidine-tagged proteins listed below. The GST-SAPKbeta clone was the generous gift of John Kyriakis and was purified over glutathione-agarose by the method of Smith and Johnson (16), as were all GST-fusion proteins listed below. Histidine-tagged ERK3 and S189T/G191Y ERK3 were constructed, expressed, and purified as described previously (11, 17). T183S ERK2, T183S/Y185G ERK2, and T183Y/Y185T ERK2 were made using the methods described (11). ERK2 into which an SpeI restriction site had been introduced (ERK2 (SpeI)), E184D ERK2, E184G ERK2, E184N ERK2, and E184P ERK2 were made by double-stranded DNA mutagenesis using a Chameleon kit (Stratagene). All mutations were confirmed by DNA sequencing. ERK2Delta 4 and E184P ERK2Delta 4 were made with PCR by using a primer to the phosphorylation lip which omitted nucleotides encoding Pro174-Asp177 (see Fig. 1B) and a C-terminal PCR primer. ERK2Delta 6 and E184G ERK2Delta 6 were made in a similar fashion except the PCR primer encoding N-terminal sequence omitted Pro174-Thr179 (see Fig. 1B) After PCR the ~600-base pair products were digested with SpeI and KpnI and subcloned into an ERK2 plasmid that had been mutagenized to contain an SpeI site just upstream of the beginning of the phosphorylation lip (ERK2(SpeI)) and which had also been digested with SpeI and KpnI. The absence of the four or six lip residues was confirmed in each construct by DNA sequencing. All mutant ERK2 proteins were histidine-tagged.

The MEK1 cDNA and the constitutively active mutants MEK1-R4F (Delta N3/S218E/S222D) and MEK2-KW71 (Delta N4/S222D/S226D) cDNAs were as described by Mansour et al. (18, 19) and were purified as described previously (21). cDNA encoding MEK2 was as described (10). A cDNA encoding MEK3 was isolated in the Guan laboratory by PCR and screening a cDNA library with MEK family oligonucleotides. GST-MEK4, GST-c-Jun (1-221), and GST-ATF2 (1-254) constructs were the generous gifts of Michael Karin. Histidine-tagged MEK5 was cloned, expressed, and purified as described previously (5). GST-MEK6 was as described (21). Myelin basic protein (MBP) was from Sigma.

Methods

Activation of MEKs

MEK1-R4F and MEK2-KW71 were constitutively active toward ERKs and thus did not need further activation (18, 19). Histidine-tagged MEK1, MEK2, and MEK3 were activated in Escherichia coli by coexpression with MEKK-C, a constitutively active fragment of MEKK1, as described previously2 (22) and were purified on nickel NTA-agarose as active kinases. GST-MEK4 was activated in vitro by preincubation with purified GST-MEKK-C. MEK5 has no known activators and thus was used directly. MEK6 possesses a high basal activity. Exposure to MEKK-C did not stimulate its activity further (data not shown; 21); MEK6 was used without any treatment to increase its activity. To activate MEK4, GST-MEK4 (15 µg/ml) was incubated with 5 µl of GST-MEKK-C for 90 min at 30 °C in kinase buffer (20 mM Tris, pH 8.0, 100 µM ATP ([gamma -32P]ATP, 25 µCi/reaction), 1 mM dithiothreitol, 1 mM benzamidine, 10 mM MgCl2). Addition of more MEKK-C or incubation for longer times did not increase phosphorylation of MEK4 (data not shown). An aliquot of the reaction was removed for MAP kinase phosphorylation assays as described below. The rest of the reaction was stopped by the addition of concentrated sample buffer and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography.

MAP Kinase Phosphorylation Assays

The amount of each MEK preparation needed to produce maximal phosphorylation of the MAP kinases was determined empirically. In most cases use of the MEK protein at ~0.1-1 µg/ml in the phosphorylation reaction was sufficient to achieve maximum phosphorylation of the MAP kinases in less than 30 min. The active MEKs were incubated with 10 µg/ml of the MAP kinases at 30 °C in kinase buffer for 90 min, three times the length of time necessary to reach maximal incorporation with wild type ERK2 (data not shown). Time courses were performed with the majority of mutants, and all seemed to reach an end point in the phosphorylation reaction by 90 min (data not shown). Initial rates of phosphorylation of mutants were similar. Aliquots of these reactions were removed for use in MAP kinase activity assays as described below. The reactions were stopped by the addition of concentrated sample buffer and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography. Bands corresponding to the MAP kinases were excised and counted by liquid scintillation.

MAP Kinase Activity Assays

To test the activity of ERK2 and the ERK2 mutants, activated ERK2 proteins at 200 ng/ml were mixed with 0.5 mg/ml MBP for 30 min at 30 °C in kinase buffer as above except 200 µM ATP was included. Reactions were stopped and analyzed as described above. The activities of p38 and SAPKbeta were tested similarly but with 0.3 mg/ml GST-ATF2 and GST-c-Jun (1-221) as substrates, respectively.

Phosphoamino Acid Analysis

One-dimensional phosphoamino acid analysis was performed as described previously (23).


RESULTS

Mutations in ERK2

To probe MEK-MAP kinase specificity we focused on the importance of the phosphorylation sites on several ERK backbones and on the structure of the phosphorylation loop. First, the sites of phosphorylation in ERK2, Thr183 and Tyr185 (TEY or wild type ERK2) were either removed or changed to other hydroxy amino acids to retain the potential for phosphorylation giving the following mutants: Y185G (TEG ERK2), T183S/Y185G (SEG ERK2), and T183S (SEY ERK2). A related ERK family member of unknown function, ERK3, is similar to ERK1/2 but contains the phosphorylation site sequence SEG. Thus we also constructed the ERK3 mutant S189T/G191Y (TEY ERK3). This class of mutants along with wild type p38 and SAPKbeta allows us to assess the importance of the phosphorylation sites on a series of different but related kinase backbone structures in the MEK-ERK interaction.

Second, we mutated the residue between the threonine and the tyrosine phosphorylation sites in ERK2. Because it has been suggested that the intervening residue between the two sites of MEK phosphorylation may direct MEK-ERK specificity, we introduced different residues into ERK2 at this position, producing E184D (TDY ERK2), E184G (TGY ERK2), E184N (TNY ERK2), and E184P (TPY ERK2) (Fig. 1B).

Third, to begin to assess the importance of lip length, we removed either four or six nonconserved amino acids from the lip of ERK2 to make it the same length as that of SAPKbeta or p38, respectively (Fig. 1B). These mutants are designated ERK2Delta 4 and ERK2Delta 6. Finally, to produce ERK2 mutants that contained lips that were more like those of p38 and SAPK, we made hybrids of intervening residue point mutants and lip length mutants to create TPY ERK2Delta 4 and TGY ERK2Delta 6.

MEK1

As reported previously, MEK1 does not phosphorylate the other family members ERK3, p38, or SAPK/JNK (Fig. 2A) (7, 24, 25, 26). The stoichiometry of phosphorylation of wild type ERK2 by MEK1 is approximately 0.8-1.0 mol/mol, consistent with previous results with in vitro phosphorylation (11, 20). It has been suggested that some percentage of bacterial wild type ERK2 is not correctly folded. Alternatively, MEK1 may require additional factors, such as MEK enhancing factor, to enable MEK to phosphorylate ERK to a stoichiometry of 2 mol/mol in vitro (27).


Fig. 2. Phosphorylation and activity of wild type MAP kinases and mutants after incubation with MEK1. Panel A, stoichiometry of phosphate incorporation into the wild type and mutant kinases by MEK1. Data are an average of 3-15 independent experiments, and standard deviations are shown. Panel B, phosphoamino acid analysis of the same kinases as in panel A after incubation with MEK1. The positions of the three phosphoamino acids, determined from internal phosphoamino acid standards, are indicated. Panel C, MBP kinase activity of the wild type and mutant ERK2s after phosphorylation by MEK1. Results are the average of multiple experiments, and standard deviations are shown.
[View Larger Version of this Image (33K GIF file)]


MEK1 phosphorylates all of the E184 ERK2 mutants nearly equally well as wild type (Fig. 2A). With wild type and the E184D, E184G, and E184N ERK2 mutants, phosphoamino acid analysis indicates that threonine and tyrosine are phosphorylated to approximately equivalent extents (Fig. 2B) with a combined stoichiometry of ~1 mol/mol on both residues. Interestingly, however, MEK1 can only phosphorylate E184P ERK2 on tyrosine (Fig. 2B); thus the stoichiometry on this residue alone must be near 1 mol/mol.

Removing four amino acids from the ERK2 lip has little effect on the ability of MEK1 to phosphorylate ERK2; ERK2Delta 4 is phosphorylated to a stoichiometry equal to wild type ERK2. The E184P ERK2Delta 4 protein is phosphorylated significantly less well by MEK1, to about 50% of wild type levels. As with E184P ERK2, only tyrosine is phosphorylated (Fig. 2B). Removal of six amino acids from the lip in ERK2, however, greatly reduces the ability of MEK1 to phosphorylate the mutant.

Changing the phosphorylatable residues of ERK2 has a more profound effect on phosphorylation by MEK1 than the other types of mutations. T183S/Y185G (SEG) ERK2 is not phosphorylated at all by MEK1 even on serine (Fig. 2, A and B). Serine phosphate seen in SEG ERK2 (Fig. 2B) is due to autophosphorylation. Interestingly, Y185G (TEG) ERK2 is phosphorylated, suggesting that the presence of the extra methyl group in threonine facilitates recognition by MEK1. T183S (SEY) ERK2 is phosphorylated on both serine and tyrosine (Fig. 2B) and retains MBP kinase activity (Fig. 2C). Thus the presence of either the tyrosine or the threonine is essential for phosphorylation by MEK1. Finally, the positioning of the residues is also important to MEK recognition, as the ERK2 mutant T183Y/Y185T (YET), in which the two residues are transposed, is not phosphorylated by MEK1 (data not shown).

MEK2

MEK2 phosphorylates wild type ERK2 to a stoichiometry of ~1.5-2 mol/mol (Fig. 3A). Like MEK1, MEK2 does not phosphorylate p38 or SAPKbeta . Also like MEK1, MEK2 can phosphorylate the Glu184 mutants as well as wild type ERK2. Again, E184P ERK2 is only phosphorylated on tyrosine (data not shown). MEK2 also phosphorylates ERK2Delta 4 and E184P ERK2Delta 4 to ~100% and ~50% of wild type, respectively. Furthermore, phosphorylation site residues in the ERK2 lip seem to have an importance similar to that with MEK1 because MEK2 phosphorylates T183S/Y185G (SEG) ERK2, Y185G (TEG) ERK2, and T183S (SEY) ERK2 to the same extent and on the same residues as does MEK1 (Fig. 3A). MEK2 phosphorylates the ERK2Delta 6 mutants to a higher extent than MEK1, although the differences are small.


Fig. 3. Phosphorylation and activity of wild type MAP kinases and mutants after incubation with MEK2. Panel A, stoichiometry of phosphate incorporation into the kinases by MEK2. Data are the average of 3-15 independent experiments, and standard deviations are shown. Panel B, phosphoamino acid analysis of ERK3 and TEY ERK3 phosphorylated by MEK2. Positions of phosphoamino acids determined from internal standards are indicated. The phosphoamino acid analysis of other MAP kinases after MEK2 phosphorylation did not differ significantly from those shown in Fig. 2B. Panel C, MBP kinase activity of the wild type and mutant ERK2s after phosphorylation by MEK2. Results are the average of multiple experiments, and standard deviations are shown.
[View Larger Version of this Image (28K GIF file)]


An unexpected finding that distinguishes MEK1 (Fig. 2A) from MEK2 (Fig. 3A) is that MEK2 is able to phosphorylate ERK3 and S189T/G191Y (TEY) ERK3. When we mutated the ERK3 phosphorylation region from SEG to TEY, the amount of phosphate incorporated increased to levels nearly equal to wild type ERK2 (Fig. 3A). Incorporation occurred primarily on threonine in the ERK3 mutant, with only a small amount incorporated onto tyrosine (Fig. 3B).

MBP Kinase Activity of ERK2 Mutants

Upon phosphorylation with either MEK1 or MEK2, E184D, E184G, and E184N ERK2 possess about 10-50% of the MBP kinase activity of wild type phosphorylated ERK2 (Figs. 2C and 3C). The E184P-containing mutants do not have MBP kinase activity presumably because they are not phosphorylated on threonine (see Fig. 2B). The lip length mutants have slightly less kinase activity than their wild type counterparts. Considering its barely detectable phosphorylation by MEK1, ERK2 Delta 6 has sufficient MBP kinase activity to suggest that it might have near wild type activity if it were more highly phosphorylated. Neither T183S/Y185G (SEG) nor Y185G (TEG) ERK2 has protein kinase activity toward MBP (Figs. 2C and 3C). ERK3, with its sequence normally SEG in the lip, also phosphorylates MBP poorly (17).

Constitutively Active MEK1 and MEK2

Previously it has been shown that deletion of a region of the MEK1 N terminus combined with replacement of conserved serines that are sites of activating phosphorylation with glutamic or aspartic acids (MEK1-R4F) greatly increases its basal activity (18). Similar mutations in MEK2 produce a similarly active form of MEK2 (MEK2-KW71) (19).

We compared the activities of these mutant, active MEKs with their phosphorylated, active wild type counterparts. The most noticeable difference between the constitutive MEKs and wild type MEKs was that the constitutively active MEK2-KW71 has now lost the ability to phosphorylate ERK3 and TEY ERK3 (data not shown). Furthermore, in a number of the intervening site mutants and lip deletion mutants, threonine is poorly recognized by both MEK1-R4F and MEK2-KW71 (data not shown). We are currently examining the differences between wild type and constitutively active MEKs in greater detail.

MEK3

When tested on our panel of proteins, MEK3 phosphorylated only p38 to high stoichiometry (Fig. 4A). MEK3 did exhibit low but reproducible activity toward SAPKbeta , ERK3, and TEY ERK3. Interestingly, MEK3 phosphorylated S189T/G191Y (TEY) ERK3 primarily on tyrosine (Fig. 4B). This is in contrast to MEK2, which phosphorylated TEY ERK3 primarily on threonine (Fig. 3B). MEK3 did not phosphorylate E184G ERK2, ERK2Delta 6, or E184G ERK2Delta 6. This is in spite of the fact that these mutants contain the same residue between the phosphorylation sites and/or a lip of the same length as p38. The ATF2 and c-Jun kinase activity of p38 was similar regardless of whether MEK3, MEK4, or MEK6 was used as the activator (Fig. 4C).


Fig. 4. Phosphorylation of wild type MAP kinases and ERK2 mutants by MEK3. Panel A, stoichiometry of phosphate incorporation into the kinases by MEK3. Data are the average of three independent experiments; the standard deviations are too small to appear on the graph. Panel B, phosphoamino acid analysis of several MAP kinases phosphorylated by MEK3. The positions of phosphoamino acid standards are indicated based on internal standards. Panel C, ATF2 and c-Jun activity of p38 and SAPKbeta after phosphorylation by MEKs.
[View Larger Version of this Image (33K GIF file)]


MEK4

MEK4 phosphorylated both p38 and SAPKbeta close to or greater than 2 mol of phosphate/mol (Fig. 5A), even though they contain a different intervening residue (TGY versus TPY). This confirms reports in the literature that both MAP kinases may be targets for MEK4 in vivo (28). Like MEK3, MEK4 does not recognize any of the ERK2 mutants, even E184P ERK2, ERK2Delta 4, and E184P ERK2Delta 4, which are designed to mimic the lip of JNK/SAPK. Phosphoamino acid analysis shows, however, that MEK4 recognizes threonine poorly in the TPY phosphorylation lip of SAPKbeta (Fig. 5B). Like p38, SAPKbeta phosphorylates both ATF2 and c-Jun with approximately equal specific activities (Fig. 4C).


Fig. 5. Phosphorylation of wild type MAP kinases and ERK2 mutants by MEK4. Panel A, stoichiometry of phosphate incorporation into the kinases. Data are the average of at least three independent experiments, and standard deviations are indicated. Panel B, phosphoamino acid analysis of p38 and SAPKbeta . Positions of phosphoamino acid standards are indicated based on internal standards.
[View Larger Version of this Image (34K GIF file)]


MEK5 and MEK6

MEK5 was tested with a number of the ERK2 mutants and did not show activity toward any of them. In fact, to date, MEK5 has not been shown to phosphorylate any member of the MAP kinase family, even its putative target MAP kinase ERK5 (5, 6). MEK6 was recently cloned as an activator of p38 (21, 29, 30, 31). In our study, p38 was the only MAP kinase phosphorylated by MEK6 (data not shown). This specificity is consistent with a physiological role for MEK6 in phosphorylation of p38.


DISCUSSION

Among the protein kinases, MEKs, the activating enzymes upstream of the MAP kinases, have a remarkable degree of specificity. They are highly selective among MAP kinase family members and recognize only the native conformation of their targets (12). We tested the specificity of the known MEK family members using ERK2, ERK3, and mutants of each as well as SAPK/JNK and p38 to examine the contributions of the phosphorylation sites, intervening residue, lip length, and backbone context of the substrate to the specificity of MEKs.

Different members of the MAP kinase family contain different intervening residues between their threonine and tyrosine phosphorylation sites. Within a MAP kinase subfamily the intervening residue remains conserved. For instance, all the members of the SAPK/JNK subfamily contain proline at this position (1). The multiple p38 kinases and the yeast homolog HOG1 contain glycine at this position (1). Because of the conservation of the intervening residue within a MAP kinase subfamily and the fact that the intervening residue is different among different MAP kinase subfamilies, it has been suggested that the role of the amino acid between the two sites of MEK phosphorylation might be to direct MEK specificity (14, 15). We tested this hypothesis by mutating E184 in ERK2 in the TEY sequence to the corresponding amino acids found in other MAP kinases (see Fig. 1B). We found that both MEK1 and MEK2 phosphorylated the Glu184 mutants as well as wild type ERK2, suggesting that the intervening residue has little or no effect on MEK1 or MEK2 specificity. Further, these changes did not allow ERK2 to be phosphorylated by other MEK family members. Thus, we conclude that the presence of a certain intervening residue will not direct a MEK to phosphorylate a different MAP kinase family member from its natural substrate. It is possible that the residue between the sites of phosphorylation may be important in other ways, such as directing phosphatase specificity, but this remains to be determined.

Members of the MAP kinase family vary in the length of their phosphorylation lips. ERK2 and ERK3 have the longest lip of the MAP kinases we studied, followed by JNK/SAPK and then p38. Structural analysis of the ERK2 phosphorylation lip revealed that it was a highly flexible structure because even the conservative mutation Tyr185 right-arrow Phe resulted in a different conformation of this lip (32, 33). Thus we considered the possibility that the length of the phosphorylation lip might be a significant determinant of lip conformation and thereby MEK specificity. Using lip deletion mutants we found that the lip length does not substantially influence the ability of MEKs to phosphorylate ERK2. One consequence of shortening the lip is that its interactions with underlying structures may be impaired. In the future we hope to probe the importance of backbone versus lip conformation further by stabilizing distinct lip conformations on the same kinase core.

Unanticipated results were obtained when MEK1 and MEK2 were tested for their abilities to phosphorylate the mutants T183S/Y185G ERK2, T183S ERK2, Y185G ERK2, and wild type ERK2. T183S/Y185G ERK2 is not phosphorylated by either MEK1 or MEK2, although Y185G ERK2 is phosphorylated by both MEK1 and MEK2. As threonine contains a beta -methyl group not present in serine, perhaps threonine in ERK2 must fit in a well defined binding pocket in the MEK active site. Phosphorylation of T183S ERK2 occurs both on serine and tyrosine, indicating that the presence of Tyr185 now allows MEK1 and MEK2 to interact with a serine at position 183. T183Y/Y185T ERK2 is not phosphorylated detectably by MEK1 or MEK2. These results may reflect structural requirements that are necessary for proper lip conformation (33). Furthermore, SEG ERK2, TEG ERK2, and wild type (SEG) ERK3 have little to no activity toward the substrate MBP. This suggests that defects in MBP kinase activity with the Tyr right-arrow Gly mutants could be due to the effect of the mutation itself on MBP kinase activity and that the phosphorylation lip may play a role in substrate specificity. To date, however, we have not found that any of the phosphorylation lip mutants becomes able to phosphorylate other MAP kinase substrates such as the N terminus of c-Jun or ATF2.

Use of ERK3 allowed us to define a significant difference in specificity between MEK1 and MEK2. Wild type ERK3 contains an SEG sequence in its phosphorylation lip, which is the site of phosphorylation by the ERK3 kinase (7). Although MEK1 could not phosphorylate ERK3 or TEY ERK3, MEK2 phosphorylated it both on serine and threonine but not tyrosine. It is curious that MEK2 cannot phosphorylate serine in an SEG motif in ERK2 but can phosphorylate serine in that motif in ERK3. The difference between MEK1 and MEK2 in their abilities to phosphorylate ERK3 in vitro is striking given recent data concerning their possible differences in vivo (34).

Our data demonstrate that the MAP kinase phosphorylation lip plays a relatively minor role in directing MEK specificity. In contrast, it appears that the kinase backbone has a major role in MEK interactions, as the backbone was the only major determinant of specificity in our experiments. Consistent with this hypothesis are results from Brunet and Pouysségur (35), who reported that in vivo pathway specificity determinants may lie in the N-terminal domain of MAP kinases.


FOOTNOTES

*   This work was supported in part by Research Grants I-1243 from the Welch Foundation and DK34128 from the National Institutes of Health (to M. H. C.) and by a postdoctoral fellowship from the Arthritis Foundation (to M. J. R.). The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   This paper is in partial fulfillment of the requirements for the Ph.D. degree.
§§   To whom correspondence should be addressed: Dept. of Pharmacology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9041. Tel.: 214-648-3627; Fax: 214-648-3811.
1   The abbreviations used are: MAP, mitogen-activated protein; ERK, extracellular signal-regulated kinase; MEK, MAP/ERK kinase; MEKK, MAP/ERK kinase kinase; SAPK, stress-activated protein kinase; JNK, c-Jun-N-terminal protein kinase; GST, glutathione S-transferase; PCR, polymerase chain reaction; MBP, myelin basic protein.
2   A. Khokhlatchev, S. Xu, J. English, P. Wu, E. Schaefer, and M. Cobb, in preparation.

Acknowledgments

We thank Amanda Weitz and Peiqun Wu for assistance with preparations of proteins and DNA sequencing, Jessie English for MEK5, Julie Wilsbacher for preparation of the MEK2-KW71 protein, and Jo Hicks for help with preparation of the manuscript.


REFERENCES

  1. Davis, R. J. (1994) Trends Biochem. Sci. 19, 470-473 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  2. Cobb, M. H., and Goldsmith, E. J. (1995) J. Biol. Chem. 270, 14843-14846 [JBC][Medline] [Free Full Text]
  3. Nishida, E., and Gotoh, Y. (1993) Trends Biochem. Sci. 18, 128-131 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  4. Herskowitz, I. (1995) Cell 80, 187-197 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  5. English, J. M., Vanderbilt, C. A., Xu, S., Marcus, S., and Cobb, M. H. (1995) J. Biol. Chem. 270, 28897-28902 [JBC][Medline] [Abstract/Free Full Text]
  6. Zhou, G., Bao, Z. Q., and Dixon, J. E. (1995) J. Biol. Chem. 270, 12665-12669 [JBC][Medline] [Abstract/Free Full Text]
  7. Cheng, M., Zhen, E., Robinson, M. J., Ebert, D., Goldsmith, E., and Cobb, M. H. (1996) J. Biol. Chem. 271, 12057-12062 [JBC][Medline] [Abstract/Free Full Text]
  8. Ahn, N. G., Seger, R., Bratlien, R. L., Diltz, C. D., Tonks, N. K., and Krebs, E. G. (1991) J. Biol. Chem. 266, 4220-4227 [Medline] [Abstract/Free Full Text]
  9. Crews, C., Alessandrini, A., and Erickson, R. (1992) Science 258, 478-480 [Medline] [Abstract/Free Full Text]
  10. Zheng, C.-F., and Guan, K.-L. (1993) J. Biol. Chem. 268, 11435-11439 [Medline] [Abstract/Free Full Text]
  11. Robbins, D. J., Zhen, E., Owaki, H., Vanderbilt, C. A., Ebert, D., Geppert, T. D., and Cobb, M. H. (1993) J. Biol. Chem. 268, 5097-5106 [Medline] [Abstract/Free Full Text]
  12. Seger, R., Ahn, N. G., Posada, J., Munar, E. S., Jensen, A. M., Cooper, J. A., Cobb, M. H., and Krebs, E. G. (1992) J. Biol. Chem. 267, 14373-14381 [Medline] [Abstract/Free Full Text]
  13. Meyerson, M., Enders, G. H., Wu, C.-L., Su, L.-K., Gorka, C., Nelson, C., Harlow, E., and Tsai, L.-H. (1992) EMBO J. 11, 2909-2917 [Medline] [Medline] [Order article via Infotrieve]
  14. Han, J., Lee, J.-D., Bibbs, L., and Ulevitch, R. J. (1994) Science 265, 808-811 [Medline] [Abstract/Free Full Text]
  15. Butch, E. R., and Guan, K.-L. (1996) J. Biol. Chem. 271, 4230-4235 [JBC][Medline] [Abstract/Free Full Text]
  16. Smith, D. B., and Johnson, K. S. (1988) Gene (Amst.) 67, 31-40 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  17. Cheng, M., Boulton, T. G., and Cobb, M. H. (1996) J. Biol. Chem. 271, 8951-8958 [JBC][Medline] [Abstract/Free Full Text]
  18. Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F., and Ahn, N. G. (1994) Science 265, 966-970 [Medline] [Abstract/Free Full Text]
  19. Mansour, S. J., Candia, J. M., Gloor, K. K., and Ahn, N. G. (1996) Cell Growth & Differ. 7, 243-250 [Medline] [Abstract]
  20. Robinson, M. J., Harkins, P. C., Zhang, J., Baer, R., Haycock, J. W., Cobb, M. H., and Goldsmith, E. J. (1996) Biochemistry 35, 5641-5646 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  21. Stein, B., Brady, H., Yang, M. X., Young, D. B., and Barbosa, M. S. (1996) J. Biol. Chem. 271, 11427-11433 [JBC][Medline] [Abstract/Free Full Text]
  22. Xu, S., Robbins, D. J., Frost, J., Dang, A., Lange-Carter, C., and Cobb, M. H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 6808-6812 [Medline] [Abstract/Free Full Text]
  23. Robbins, D. J., and Cobb, M. H. (1992) Mol. Biol. Cell. 3, 299-308 [Medline] [Abstract]
  24. Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. (1994) Cell 76, 1025-1037 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  25. Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Ahmad, M. F., Avruch, J., and Woodgett, J. R. (1994) Nature 369, 156-160 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  26. Rouse, J., Cohen, P., Trigon, S., Morange, M., Alonso-Llamazares, A., Zamanillo, D., Hunt, T., and Nebreda, A. R. (1994) Cell 78, 1027-1037 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  27. Scott, A., Haystead, C. M. M., and Haystead, T. A. J. (1995) J. Biol. Chem. 270, 24540-24547 [JBC][Medline] [Abstract/Free Full Text]
  28. Dérijard, B., Raingeaud, J., Barrett, T., Wu, J.-H., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) Science 267, 682-685 [Medline] [Abstract/Free Full Text]
  29. Han, J., Lee, J.-D., Jiang, Y., Li, Z., Feng, L., and Ulevitch, R. J. (1996) J. Biol. Chem. 271, 2886-2891 [JBC][Medline] [Abstract/Free Full Text]
  30. Moriguchi, T., Kuroyanagi, N., Yamagachi, K., Gotoh, Y., Irie, K., Kano, T., Shirakabe, K., Muro, Y., Shibuya, H., Matsumoto, K., Nishida, E., and Hagiwara, M. (1996) J. Biol. Chem. 271, 13675-13679 [JBC][Medline] [Abstract/Free Full Text]
  31. Raingeaud, J., Whitmarsh, A. J., Barrett, T., Dérijard, B., and Davis, R. J. (1996) Mol. Cell. Biol. 16, 1247-1255 [Medline] [Abstract]
  32. Zhang, F., Strand, A., Robbins, D., Cobb, M. H., and Goldsmith, E. J. (1994) Nature 367, 704-711 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  33. Zhang, J., Zhang, F., Ebert, D., Cobb, M. H., and Goldsmith, E. J. (1995) Structure 3, 299-307 [Medline]
  34. Wu, X., Noh, S. J., Zhou, G., Dixon, J. E., and Guan, K.-L. (1996) J. Biol. Chem. 271, 3265-3271 [JBC][Medline] [Abstract/Free Full Text]
  35. Brunet, A., and Pouysségur, J. (1996) Science 272, 1652-1655 [Medline] [Abstract]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Virol.Home page
M. Cannon, N. J. Philpott, and E. Cesarman
The Kaposi's Sarcoma-Associated Herpesvirus G Protein-Coupled Receptor Has Broad Signaling Effects in Primary Effusion Lymphoma Cells
J. Virol., December 6, 2002; 77(1): 57 - 67.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. L. Robinson, A. W. Whitehurst, M. Raman, and M. H. Cobb
Identification of Novel Point Mutations in ERK2 That Selectively Disrupt Binding to MEK1
J. Biol. Chem., April 19, 2002; 277(17): 14844 - 14852.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. P. Herbert, A. R. Tee, and C. G. Proud
The Extracellular Signal-regulated Kinase Pathway Regulates the Phosphorylation of 4E-BP1 at Multiple Sites
J. Biol. Chem., March 22, 2002; 277(13): 11591 - 11596.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. J. Robinson, B.-e Xu, S. Stippec, and M. H. Cobb
Different Domains of the Mitogen-activated Protein Kinases ERK3 and ERK2 Direct Subcellular Localization and Upstream Specificity in Vivo
J. Biol. Chem., February 8, 2002; 277(7): 5094 - 5100.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
G. Pearson, F. Robinson, T. Beers Gibson, B.-e Xu, M. Karandikar, K. Berman, and M. H. Cobb
Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions
Endocr. Rev., April 1, 2001; 22(2): 153 - 183.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
Z. Chen, M. Hutchison, and M. H. Cobb
Isolation of the Protein Kinase TAO2 and Identification of Its Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase Binding Domain
J. Biol. Chem., October 1, 1999; 274(40): 28803 - 28807.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. L. Wilsbacher, E. J. Goldsmith, and M. H. Cobb
Phosphorylation of MAP Kinases by MAP/ERK Involves Multiple Regions of MAP Kinases
J. Biol. Chem., June 11, 1999; 274(24): 16988 - 16994.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Tokumitsu, N. Takahashi, K. Eto, S. Yano, T. R. Soderling, and M.-a. Muramatsu
Substrate Recognition by Ca2+/Calmodulin-dependent Protein Kinase Kinase. ROLE OF THE ARG-PRO-RICH INSERT DOMAIN
J. Biol. Chem., May 28, 1999; 274(22): 15803 - 15810.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. W. Ramos, T. K. Kojima, P. E. Hughes, C. A. Fenczik, and M. H. Ginsberg
The Death Effector Domain of PEA-15 Is Involved in Its Regulation of Integrin Activation
J. Biol. Chem., December 18, 1998; 273(51): 33897 - 33900.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Hutchison, K. S. Berman, and M. H. Cobb
Isolation of TAO1, a Protein Kinase That Activates MEKs in Stress-activated Protein Kinase Cascades
J. Biol. Chem., October 30, 1998; 273(44): 28625 - 28632.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. M. English, G. Pearson, R. Baer, and M. H. Cobb
Identification of Substrates and Regulators of the Mitogen-activated Protein Kinase ERK5 Using Chimeric Protein Kinases
J. Biol. Chem., February 13, 1998; 273(7): 3854 - 3860.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Jiang, Z. Li, E. M. Schwarz, A. Lin, K. Guan, R. J. Ulevitch, and J. Han
Structure-Function Studies of p38 Mitogen-activated Protein Kinase. LOOP 12INFLUENCES SUBSTRATE SPECIFICITY AND AUTOPHOSPHORYLATION, BUT NOT UPSTREAM KINASE SELECTION
J. Biol. Chem., April 25, 1997; 272(17): 11096 - 11102.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Z. Wang, P. C. Harkins, R. J. Ulevitch, J. Han, M. H. Cobb, and E. J. Goldsmith
The structure of mitogen-activated protein kinase p38 at 2.1-A resolution
PNAS, March 18, 1997; 94(6): 2327 - 2332.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Karandikar, S. Xu, and M. H. Cobb
MEKK1 Binds Raf-1 and the ERK2 Cascade Components
J. Biol. Chem., December 15, 2000; 275(51): 40120 - 40127.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. J. Bardwell, L. J. Flatauer, K. Matsukuma, J. Thorner, and L. Bardwell
A Conserved Docking Site in MEKs Mediates High-affinity Binding to MAP Kinases and Cooperates with a Scaffold Protein to Enhance Signal Transmission
J. Biol. Chem., March 23, 2001; 276(13): 10374 - 10386.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robinson, MeganJ.
Right arrow Articles by Cobb, MelanieH.
Right arrow Search for Related Content
PubMed